Life Sciences News Feeds
Scientific Advancements
- Dyadic and Scripps Research Collaborate on RapidResponse Hantavirus Antibody and Vaccine Development29 May 2026, 5:47 pm
May 28, 2026 | Press ReleasesCollaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic ProductionJUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE)...
- Ziptek Introduces Breakthrough ZipE® Biolock™ Technology, Redefining Tissue Repair Worldwide14 April 2026, 4:18 pm
SARASOTA, Fla., April 9, 2026 /PRNewswire/ -- Ziptek, an emerging international medical device innovator, today announced significant clinical and commercial momentum for its revolutionary ZipE® Biolock™ technology—a first-of-its-kind, resorbable tissue...
- Dyadic and Fermbox Bio Launch First Product Under Expanded Collaborationi4 March 2026, 6:09 pm
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)Mar 4, 2026 | Press ReleasesJUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) —...
- Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization2 March 2026, 1:46 pm
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development MilestoneJUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) — Dyadic...
- Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events24 February 2026, 8:00 pm
February 24, 2026 08:30 ET | Source: Cadrenal Therapeutics Inc.Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no...
Business Achievements
- NanoNeurosciences Reaches a Landmark FDA Milestone, Accelerating the Path to the Clinic23 July 2026, 3:54 pm
NanoNeurosciences is proud to announce the completion of its Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead candidate, NNS-01, a landmark achievement...
- Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential7 July 2026, 4:00 pm
C1 Monoclonal Antibody Progress for RSV and MalariaFollowing Full $3.1 Million Gates Foundation Grant FundingJUPITER, Fla. — July 7, 2026 — Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a...
- FORGE Coalition Launches to Position Tampa Bay as Southeast Hub for Radiopharmaceutical Innovation,28 May 2026, 3:01 pm
FORGE Coalition Launches to Position Tampa Bay as Southeast Hub for Radiopharmaceutical Innovation, Training and ProductionMay 26, 2026TAMPA, Fla. (May 27, 2026) — A new regional coalition, the Florida Oncology...
- Omeza announces closing of $8.5 Million Series A financing21 April 2026, 3:25 pm
Omeza announces closing of $8.5 Million Series A financing co-led by Astanor and BluKap Ventures, with participation from Catalyst Investments Round positions Omeza to accelerate clinical development and scale...
- Defence Therapeutics Announces Closing Of Private Placement Of Units For Gross Proceeds Of$9,595,00031 March 2026, 9:51 pm
March 9, 2026Montreal, QC, Canada, March 9, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company,...
People on the Move
- AllerGene AI Therapeutics Appoints Biotech Industry Veteran Gad Berdugo to Board of Directors11 June 2026, 4:04 pm
MIAMI, June 9, 2026 /PRNewswire/ -- AllerGene AI Therapeutics, a biotechnology company developing first-in-class in vivo targeted-lipid nanoparticle (tLNP) mRNA chimeric antigen receptor (CAR) therapies designed to prevent and treat...
- US biotech innovator Dyadic appoints Intralink to accelerate European growth plans4 June 2026, 1:30 pm
US biotechnology company Dyadic Applied BioSolutions has appointed Intralink to support its expansion across Europe.Florida-based Dyadic develops precision-engineered, animal-free proteins and enzymes for the life sciences, food and nutrition and...
- David Dickens, MD, FAAP, Named Chief of Hematology/Oncology for Nemours Children’s Hospital, FL6 April 2026, 7:05 pm
ORLANDO, Florida (March 30, 2026) - Nemours Children’s Health today announced the appointment of David Dickens, MD, FAAP, as Division Chief of Hematology/Oncology for Nemours Children’s Hospital, Florida.“Dr. Dickens brings...
- CGU Levels Up with Levan Center Leadership21 August 2025, 4:01 pm
Dear Giants & Unicorns, Big news - our co-founder, Michael Burtov, has been appointedChief Innovation Officer at Nova Southeastern UniversityandExecutive Director of the Alan B. Levan | NSU Broward Center of...
- Moffitt Cancer Center Announces Dr. Josh Carpenter as President of SPEROS FL12 March 2025, 4:36 pm
Moffitt Cancer Center Announces Dr. Josh Carpenter as President of SPEROS FLMarch 11, 2025TAMPA, Fla. — Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, and its wholly...
Industry Data
- LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids12 March 2025, 4:32 pm
LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories — Investment Expands Company’s CDMO Facilities and Services to Meet Growing Demand for Domestic Drug...
- Is Your Company Ready for Expanded R&D Tax Credit Reporting?2 January 2025, 3:20 pm
Is Your Company Ready for Expanded R&D Tax Credit Reporting?Tax strategies 12/20/2024Key insightsThe IRS has proposed a change to Form 6765 — the form used to claim the R&D tax...
- President Passidomo, Senators Burton and Harrell Announce “Live Healthy” Proposal to Grow Florida’s7 December 2023, 2:04 pm
President Passidomo, Senators Burton and Harrell Announce “Live Healthy” Proposal to Grow Florida’s Health Care Workforce Legislation Reduces Regulatory Hurdles and Makes Key Investments to Increase Access and Incentivize Innovation Tallahassee–Florida...
- UF BME UNDERGRADUATE PROGRAM ACHIEVES #10 RANKING IN THE U.S. NEWS RANKINGS13 November 2023, 2:04 pm
UF BME UNDERGRADUATE PROGRAM ACHIEVES #10 RANKING IN THE U.S. NEWS RANKINGS November 13, 2023 in BME News The J. Crayton Pruitt Family Department of Biomedical Engineering has achieved its...
- Biden-Harris Administration Announces New Action Plan to Bolster, Expand, and Diversify America’s B27 June 2023, 2:31 pm
FACT SHEET: Biden-Harris Administration Announces New Action Plan to Bolster, Expand, and Diversify America’s Biotechnology and Biomanufacturing Workforce HOMEOSTPNEWS & UPDATESPRESS RELEASES Today, the Biden-Harris Administration is releasing a new action...
Industry Events
- Florida Chamber: Nominations Now Open for Coolest Thing Made in Florida14 April 2026, 2:06 pm
Nominations Are Now OpenIn partnership with FloridaCommerce, the Florida Chamber of Commerce launches the 2nd annual Coolest Thing Made in Florida—a statewide competition highlighting the innovation, talent, and economic impact of products...
- Biorep Technologies Marks 40th Anniversary of the Ricordi® Chamber, Reinforcing Its Leadership26 March 2026, 3:44 pm
Biorep Technologies Marks 40th Anniversary of the Ricordi® Chamber, Reinforcing Its Leadership in Life Sciences Manufacturing ExcellenceNews provided byBiorep Technologies, Inc. Feb 25, 2026, 10:00 ET- Landmark pancreatic islet isolation...
- Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida9 January 2026, 6:21 pm
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investmentJan 09, 2026New 35,000-square-foot facility in Winter Park will...
- Life Sciences Innovators Convene at BioFlorida's 28th Annual Innovation Conference2 December 2025, 2:18 pm
Conference underscores Florida's leadership in Life Sciences while charting strategic pathways for continued growthORLANDO, Fla., Dec. 1, 2025 /PRNewswire/ -- Approximately 500 life sciences leaders convened at Florida's Annual Innovation Conference, powered by BioFlorida, to...
- Life Sciences Leaders Unite at BioFlorida's Thriving Annual Conference26 November 2024, 2:55 am
Life Sciences Leaders Unite at BioFlorida's Thriving Annual Conference Annual Conference spotlights the state's successes while also solidifying a course for the futureORLANDO, Fla., Nov. 25, 2024 /PRNewswire/ -- The 27th BioFlorida Annual...
Advocacy
- ProChile and BioFlorida Announce Strategic Partnership5 January 2026, 6:08 pm
Public-Private Alliance to Advance International Collaboration Between Chile and Florida's Life Sciences EcosystemsMIAMI and SANTIAGO, Chile, Jan. 5, 2026 /PRNewswire/ -- ProChile, the Chilean government agency responsible for promoting the...
- Buchanan, Tonko Introduce Legislation to Expand Alzheimer’s Screening and Prevention24 November 2025, 9:03 pm
November 19, 2025Delivers Life-Changing Early Detection for 580,000 Floridians Living with Alzheimer’sWASHINGTON — Today, Congressman Vern Buchanan, Vice Chairman of the House Ways and Means Committee and Chair of the...
- Governor Ron DeSantis and First Lady Casey DeSantis Announce $60 Million Cancer Research Funding26 September 2025, 9:31 pm
TAMPA, Fla. – Today, Governor Ron DeSantis and First Lady Casey DeSantis visited the University of South Florida to attend the Department of Health’s World Cancer Research Day symposium to...
- FloridaCommerce Announces an Additional $167 Million Available For Florida Small Business through th6 January 2025, 12:38 pm
For Immediate Release: January 6, 2025 FloridaCommerce Announces an Additional $167 Million Available For Florida Small Business through the State Small Business Credit Initiative 2.0 ~ Since January 2023, Florida...
Other
- Beyond The Cleanroom Why Commercial Manufacturing Success Begins Long Before Construction15 July 2026, 8:47 pm
Executive SummaryThe life sciences industry has never had more access to capital, technology, engineering expertise, or construction capability than it does today. Pharmaceutical companies, biotechnology firms, contract development and manufacturing...
- Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor Meetings10 June 2026, 7:03 pm
June events include USA trade mission to Norway (Oslo), the EHA Annual Meeting (Stockholm) and BIO International Convention (San Diego) BOCA RATON, FLORIDA & STOCKHOLM, SWEDEN – June 4, 2026...
- Static Reimbursement Structures Aren't Enough. Patients Need Whole-Person Support28 April 2026, 7:09 pm
By Donna Libretti Cooke, JD, chief impact officer and owner, ImpactSphere Clinical, LLC; Erin Miller, senior director, Angel Center of Excellence, Tigerlily Foundation; and Jeanne M. Regnante, founder and CEO,...
- CleanSpace to Unveil Nation's Largest Working Cleanroom13 April 2026, 4:35 pm
CleanSpace unveils a fully operational modular pharmaceutical cleanroomat INTERPHEX, showcasing live manufacturing, compliance, and speed tomarket worldwide..CleanSpace, a leader in modular cleanroom design, engineering, and construction, announces the debut of...
- Moffitt Cancer Center Recognized as a Tampa Bay Times Top Workplace for the 15th Time4 April 2026, 12:03 pm
March 31, 2026TAMPA, Fla. —Moffitt Cancer Center has been recognized as one of the Tampa Bay Times Top Workplaces for 2026, marking the 15th time Moffitt has earned this prestigious honor. The Top Workplaces list...
- Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 204130 July 2026, 12:05 pm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has a
- Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress30 July 2026, 12:00 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2026, and reviewed recent business highlights. “During the first half of 2026, we continued to meaningfully advance our business, generating over $1 billion in quarterly product revenues for the first time in our history during the first quarter and, building on that momentum, over $1 billi
- Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 202630 July 2026, 12:00 pm
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Ti
- Natera to Report its Second Quarter Results on August 6, 202630 July 2026, 12:00 pm
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2026, after the market closes on August 6, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera’s Second Quarter 2026 Financial Results Date: August 6, 2026 Time: 1:30 p.m. PT (4:30 p.m. ET) Liv
- Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis30 July 2026, 12:00 pm
PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective oral small molecule antagonist of MRGPRX2, EVO756, for the prophylactic treatment of migraine. "Initiating this migraine trial is an exciting mileston
- Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply30 July 2026, 12:00 pm
CINCINNATI--(BUSINESS WIRE)--Resilience today announced it has expanded its strategic partnership with Eli Lilly and Company to increase U.S. production of critical medicines.
- Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia30 July 2026, 12:00 pm
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to enzomenib (DSP-5336) for the treatment of patients with acute lymphoblastic leukemia (ALL). Enzomenib is an investigational, oral, small molecule inhibitor of the menin and lysine (K)-specific methyltransferase 2A (KMT2A) protein interaction, a key interaction in acute leukemia and other tumor cell proliferation and gro
- Enhanced Announces Significant Expansion of Supplement Line to 33 International Markets30 July 2026, 11:30 am
NEW YORK--(BUSINESS WIRE)---- $ENHA #Enhanced--Enhanced Group Inc. (NYSE: ENHA) the personalized performance products and elite sports competition company today announced the international expansion of its direct-to-consumer supplement business, making its Stronger+ and Longer+ products available for the first time to customers in 33 countries beyond the United States. The expansion covers 27 European Union member states, the United Kingdom, Canada, Australia, Mexico, Japan and Colombia, and represents a significa
- Baxter Reports Second-Quarter 2026 Results30 July 2026, 11:15 am
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2026. “Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance,” said Andrew Hider, president and CEO. “While we’re encouraged by this steady progress and core operating momentum, we remain
- Palmless™ by C16 Biosciences Launches First Food Ingredient and Expands Beauty Portfolio30 July 2026, 11:10 am
NEW YORK--(BUSINESS WIRE)--C16 Biosciences, the makers of Palmless™, Launches First Food Ingredient and Expands Beauty Portfolio
- SoundHealth Raises $12.25M to Accelerate Growth of Its AI-Enabled Non-Invasive Devices for Breathing and Sleep Disorders30 July 2026, 11:00 am
SAN FRANCISCO--(BUSINESS WIRE)--SoundHealth, a leader in personalized, AI-enabled non-invasive medical and wellness devices, announced the closing of an oversubscribed Series A financing led by Shangbay Capital, bringing the company's total funding to date to $12.25 million. The new capital will accelerate growth of SoundHealth's portfolio of personalized, FDA-cleared therapeutics designed to treat population scale breathing; and wellness devices targeted towards sleep disorders. SoundHealth's
- HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time30 July 2026, 11:00 am
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time
- Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential30 July 2026, 11:00 am
LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva Bio” or the “Company”), a clinical-stage biotechnology company advancing the development of a portfolio of once-weekly oral candidates for obesity and obesity-related disorders, today announces that the first patient has been dosed in a Phase 1 SAD study evaluating VRB-103, a once-weekly selective oral amylin analog, as a treatment for overweight and obesity. The Phase 1 randomized, double-blind, placebo-controlled study wil
- Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results30 July 2026, 11:00 am
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. “We are pleased with the progress we made during the second quarter. Our financial discipline with refined focus on nuzefatide pevedotin and our nex
- Henry Schein Announces Leadership Transitions30 July 2026, 11:00 am
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that it is creating the Henry Schein Leadership Team (HSLT) to replace its Executive Management Committee. The Company will also integrate its global supply chain organization with its global distribution group. The new leadership structure will continue to develop the Company’s strategic priorities, accelerate its execution, and enhance enterprise collaboration. “I am pleased to announce a new leadership structu
- Bristol Myers Squibb Reports Second Quarter Financial Results for 202630 July 2026, 10:59 am
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
- Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo30 July 2026, 10:45 am
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from two Phase 3 trials evaluating the efficacy and safety of LITFULO once daily in patients with both active and stable nonsegmental vitiligo (NSV) and who had a broad range of disease severity. The TRANQUILLO study included patients aged 12 years and older, while TRANQUILLO 2 enrolled adults only. Across the studies, both the 50 and 100 milligram doses of LITFULO delivered significant, clinically meani
- Butterfly Network Reports Second Quarter 2026 Financial Results30 July 2026, 10:30 am
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, "Butterfly delivered another outstanding quarter, exceeding the high end of our guidanc
- Omnicell Announces Second Quarter 2026 Financial Results30 July 2026, 10:30 am
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Second Quarter 2026 Financial Results
- TIXiMED Appoints Stephen Daly and Albert R. Collinson, Ph.D., to Board of Directors30 July 2026, 10:00 am
BIRMINGHAM, Ala.--(BUSINESS WIRE)-- #T1D--TIXiMED, Inc., a clinical-stage pharmaceutical company developing TIX100 as a first-in-class oral inhibitor of thioredoxin-interacting protein (TXNIP) for diabetes and metabolic disease, today announced the appointment of Stephen E. Daly and Albert R. Collinson, Ph.D., to its Board of Directors. Both directors bring extensive experience in the development and commercialization of diabetes and metabolic-disease therapeutics, further strengthening the company’s
- Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track30 July 2026, 6:37 am
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter
- Iksuda receives US FDA IND clearance for IKS0430 July 2026, 6:00 am
NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IKS04, a CA242-directed ADC, enabling assessment in a Phase 1 trial in patients with gastrointestinal (GI) cancers. CA242 is a tumour-specific glycotope which is strongly expressed in a variety of GI cancers including the majority of color
- Align Technology Hosts 2026 Invisalign® Ortho Summit, Showcasing a “Beyond Possible” Vision for Connected Digital Orthodontics29 July 2026, 10:45 pm
LAS VEGAS & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from its 2026 Invisalign® Ortho Summit, held July 23–26, 2026 in Las Vegas. The Summit brought together more than 500 orthodontists and practice team members for an
- ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer29 July 2026, 10:45 pm
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA® (nogapendekin alfa inbakicept) across two indications. The authorization covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC, and ANKTIVA 1.2 mg in combination wit
- Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T29 July 2026, 9:45 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #InVivoCART--Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T
- Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation29 July 2026, 9:42 pm
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS
- Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration29 July 2026, 9:30 pm
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplified to a single subcutaneous (SC) injection per visit. During a Type C meeting with the U.S. Food and Drug Administration in May 2026, the Company d
- Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset29 July 2026, 9:28 pm
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application of Sail's in vivo CAR-T platform across additional therapeutic targets over
- Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain29 July 2026, 9:08 pm
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines, today announced the publication of positive results from the abdominoplasty clinical trial evaluating LTG-001 for the treatment of moderate-to-severe acute postoperative pain as an original research article in the New England Journal of Medicine (NEJM). LTG-001 is an investigational selective Nav1.8 inhibitor, part of a new cl
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)29 July 2026, 9:00 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to employment to Michael Severino, M.D. as Chief Executive Officer of Sarepta. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). Dr. Se
- Align Technology Announces Strategic Initiatives Consistent with Long-term Growth and Shareholder Value Creation Objectives29 July 2026, 8:45 pm
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced several initiatives reflecting its commitment to strong corporate governance and shareholder value creation. Following discussions with Elliott Investment Management L.P. (toge
- Align Technology Announces Second Quarter 2026 Financial Results29 July 2026, 8:36 pm
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the second quarter ("Q2'26"). Q2'26 total revenues were $1,056.2 million, up 1.5% sequentially and up 4.3% year-over-year. Q2'26 total revenues were unfavorably imp
- European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union29 July 2026, 8:30 pm
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medic
- UFP Technologies to Report Second Quarter 2026 Financial Results on August 3, 202629 July 2026, 8:20 pm
NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today announced that the Company plans to report results for the second quarter on Monday, August 3rd, after the close of the stock market. The Company will hold a conference call to discuss the results on the following day, August 4th,
- Teleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried Plasma29 July 2026, 8:15 pm
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has received Biologics License Application (BLA) approval for EZPLAZ™ Freeze Dried Plasma (FDP) from the U.S. Food and Drug Administration (FDA). EZPLAZ™ FDP is approved for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled bleeding (hemorrhage), when plasma is required and other pla
- ICON Reports Second Quarter 2026 Results29 July 2026, 8:15 pm
DUBLIN--(BUSINESS WIRE)--ICON Reports Second Quarter 2026 Results
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update29 July 2026, 8:05 pm
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2026. Financial Results “Our oncology and Cushing’s syndrome businesses delivered strong results in the second quarter. In our oncology busi
- Guardant Health to Participate in Upcoming Investor Conferences29 July 2026, 8:05 pm
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Canaccord Genuity 46th Annual Growth Conference in Boston, MA Fireside chat on Wednesday, August 12th at 3:00 p.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY Fireside chat on Tuesday, September 15th at 7:45 a.m. Eastern Time Interested parties may access liv
- Myomo to Report Second Quarter 2026 Financial Results on August 529 July 2026, 8:05 pm
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter ended June 30, 2026 on Wednesday, August 5, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and an
- CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance29 July 2026, 8:05 pm
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a constant currency(2) basis. Excluding the impact of the Company’s previously announced strategic exits of GI product offerings, net sales increased 6.0% on an organic cons
- TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference29 July 2026, 8:05 pm
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Canaccord Genuity 46th Annual Growth Conference. Management will participate in one-on-one meetings o
- KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference29 July 2026, 8:05 pm
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026. KORU Medical's management is scheduled to present at the Canaccord Genuity 46th Annual
- Glaukos Announces Second Quarter 2026 Financial Results29 July 2026, 8:05 pm
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include: Record net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis and 49% year-over-year on a constant currency basis. Glaucoma record ne
- Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 202629 July 2026, 8:01 pm
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
- Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter29 July 2026, 8:01 pm
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR) (“Xencor”), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced its agreement with Alexion Pharma International Operations Limited, an Irish limited company (“Alexion”), to resolve a commercial dispute related to U.S. royalties on Ultomiris® (ravulizumab-cwvz) (the “Settlement Agreement”).Under the Settlement Agreement, Xencor will receive $10
- Children Who Once Waited Months for an MRI at Luskin Orthopaedic Institute for Children May Soon Wait Just Days29 July 2026, 6:40 pm
LOS ANGELES--(BUSINESS WIRE)-- #AdvancedImagingCenter--$24 Million Investment Will Expand Pediatric Care and Bring Next-Generation MRI Technology to LuskinOIC in Downtown Los Angeles
- Hims & Hers Responds to FTC Lawsuit29 July 2026, 5:51 pm
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) responded to the lawsuit filed today by the Federal Trade Commission (FTC): This lawsuit disregards substantial evidence we provided the FTC during its nearly three-year investigation, ignores established state laws and industry standards in telehealth, and contorts the law to try to manufacture claims. This is not enforcement grounded in consumer protection; it is an effort to generate headlines at our expense. We are co
- RDi USA Inc. Launches at ADLM 2026, Bringing Automated Diagnostic Kitting and Connected Self-Sampling Pathways to the U.S.29 July 2026, 5:46 pm
ANAHEIM, Calif.--(BUSINESS WIRE)--RDi today announced the launch of RDi USA Inc. at the ADLM 2026 Clinical Lab Expo, where the new U.S. business will make its official industry debut at Booth #4454 from July 28–30. RDi USA has been created to help laboratories, diagnostic manufacturers, healthcare providers, screening organizations and research partners overcome one of the largest barriers to scaling diagnostic testing: the fragmented infrastructure surrounding the test itself, for partners ope
- Good Neighbor Pharmacy® Named #1 in Customer Satisfaction with Chain Drug Store Pharmacies and Most Trusted by JD Power29 July 2026, 5:41 pm
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Good Neighbor Pharmacy, a national franchise for independent pharmacies offered through Cencora, has been ranked “#1 in Customer Satisfaction with Chain Drug Store Pharmacies” in the JD Power 2026 U.S. Pharmacy StudySM, a syndicated benchmarking study profiling the experiences of customers of the largest pharmacies in the United States. In addition to ranking highest overall, Good Neighbor Pharmacy ranked highest across four of seven dimensions: Pharmacy offe
- ORNL, REV Launch Innovative Collaboration on Fusion Infrastructure29 July 2026, 4:00 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Department of Energy’s Oak Ridge National Laboratory (ORNL) and fusion energy consultancy Rutherford Energy Ventures LP (REV) have officially begun development of a new public-private partnership framework to create shared fusion testbed infrastructure at ORNL. The new consortium model, known as the Fusion Upscaled Leveraged Consortia for Rapid Acceleration (FULCRA), is designed to address key gaps identified in the DOE Fusion Science and Technology Roadma
- Merck Announces Fourth-Quarter 2026 Dividend29 July 2026, 3:04 pm
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Fourth-Quarter Dividend
- Full Spectrum Achieves 50 Percent Growth, Expands Client Portfolio, and Moves to New Headquarters29 July 2026, 2:22 pm
WESTBOROUGH, Mass.--(BUSINESS WIRE)-- #healthcare--Full Spectrum, a rapidly growing product development and consulting company specializing in the medical device, digital health, and life science industries, today announces significant growth and expansion at the mid-year mark, with the organization growing by 50 percent compared to this time last year, the addition of 12 new clients, and the strengthening of existing customer relationships. To support its continued momentum, the company has moved to larger
- Datavault AI Expands Data Driven Outcome Healthcare-focused Blockchain and Data Monetization License With DataMeds AI29 July 2026, 2:18 pm
PHILADELPHIA--(BUSINESS WIRE)---- $DVLT #DatavaultAI--Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ: DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA’) tokenization technologies, today announced that it has amended its definitive agreement with DataMeds AI, Inc. (NASDAQ: MEDS) (“DataMEDS”) to expand its PharmacyChain blockchain-related technology licensing relationship beyond pharmaceutical distribution to include all unencumbered commercial healthcar
- Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 202629 July 2026, 2:15 pm
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil. Multiple studies span long-term outcomes, real-world use, injection experience, adherence and future long-acting options for HIV treatment and prevention. Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said: “The data
- Science Corp. Names Nevada Sanchez as Executive Vice President of Engineering29 July 2026, 2:00 pm
ALAMEDA, Calif.--(BUSINESS WIRE)--Science Corporation, the full-stack neural engineering and brain-computer interface (BCI) company focused on restoring and extending life, today announced the appointment of Nevada Sanchez as Executive Vice President of Engineering. Sanchez will provide engineering leadership across the organization and will report directly to Science CEO and co-founder Max Hodak. Sanchez co-founded Butterfly Network, Inc. (NYSE: BFLY) in 2011, and until recently served as Seni
- Massive Bio and QC Healthcare Announce National Collaboration to Transform Cancer Patient Access29 July 2026, 2:00 pm
BOCA RATON, Fla. & CHARLOTTE, N.C. & ATLANTA--(BUSINESS WIRE)--Massive Bio, Inc., a leader in AI-enabled oncology clinical trial matching and patient navigation, and QC Healthcare, LLC, a nationwide company focused on telehealth, clinical research, pharmacy services, artificial intelligence, healthcare analytics, and population health, today announced a strategic collaboration to fundamentally reshape how cancer patients access clinical trials, coordinated care, and telehealth support throughou
- AICure Expands Executive Leadership to Accelerate AI-Powered Medication Adherence, Remote Weight Verification, and Enterprise White-Label Solutions29 July 2026, 2:00 pm
HOUSTON--(BUSINESS WIRE)--AICure today announced the appointments of Anand Ramaswamy as Chief Product Officer and Olinka Greene as Director of Quality Assurance and Management. Together, these leadership appointments support AICure's continued expansion of its AI-powered medication adherence platform, recently launched WeightVerify for remote weight verification and monitoring, and enterprise white-label solutions for life sciences, healthcare organizations, and digital health partners across o
- VB Spine Receives FDA Clearances of Expanded Indications for Vitoss® Bone Graft Substitute and Interbody Cage Portfolio29 July 2026, 1:40 pm
NEW YORK--(BUSINESS WIRE)--VB Spine LLC (“VB Spine”) today announced that the U.S. Food and Drug Administration (FDA) granted two 510(k) clearances that expand the indications for its Vitoss® Bone Graft Substitute and interbody cage portfolio. The clearances allow Vitoss® to be used in the intervertebral disc space with interbody cages and expand the indications for VB Spine’s interbody cages to include use with bone void fillers cleared for use in intervertebral body fusion procedures, includi
- VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System29 July 2026, 1:00 pm
MAPLE GROVE, Minn.--(BUSINESS WIRE)--VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled and treated in the TRIVITA US IDE pivotal study of the TriNova™ system. The randomized controlled study will compare TriNova head-to-head with the commercially available Edwards EVOQUE™ TTVR system. The TRIVITA trial (NCT07516444) initiation marks a significant
- Adjuvia Therapeutics Closes $8 Million Series Seed Financing to Advance Novel Mitochondrial Disease Therapy into the Clinic29 July 2026, 1:00 pm
SAN FRANCISCO--(BUSINESS WIRE)-- #AdjuviaTherapeutics--Adjuvia Therapeutics raises $8 million to advance ATI-105, a novel mitochondrial disease therapy, into Phase 1 clinical trials.
- Landmark Bio and Syngoi Technologies to Operate as Artis BioSolutions, an End-to-end Gene-to-GMP Platform for Genetic Medicines29 July 2026, 1:00 pm
SAN DIEGO--(BUSINESS WIRE)-- #ArtisBioSolutions--Artis BioSolutions, an advanced therapies company built to streamline the discovery, development, and production of genetic medicines, today announced that both Landmark Bio, its Watertown, Massachusetts-based development and GMP manufacturing operation, and Syngoi, its Bilbao, Spain-based enzymatic synthetic DNA business, will now operate under the Artis BioSolutions name. The change unifies Artis' U.S. and European capabilities under a single brand, completing a tr
- Feinstein Summer Concert raises $3.5 million to advance groundbreaking medical research29 July 2026, 1:00 pm
OLD WESTBURY, N.Y.--(BUSINESS WIRE)--The Feinstein Institutes for Medical Research, the home of research at Northwell Health, raised $3.5 million at its 21st annual Feinstein Summer Concert to support groundbreaking scientific discoveries and innovation, bringing the event’s total fundraising to nearly $50 million since its inception. Held on July 23 at Old Westbury Gardens, the evening welcomed supporters of the Feinstein Institutes and featured a performance by multiplatinum indie pop band, A
- QT Imaging Appoints Medical Imaging and Digital Health Executive Dr. Julia Albright as Chief Science Officer29 July 2026, 12:30 pm
NOVATO, Calif.--(BUSINESS WIRE)---- $QTI #BreastCancer--QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced the appointment of Julia Albright, Ph.D., as Chief Science Officer (“CSO”), effective July 27, 2026. Dr. Albright brings more than 25 years of experience spanning medical imaging, digital health, oncology, cloud technologies, and the development
- Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease29 July 2026, 12:30 pm
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. The patent includes
- CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance29 July 2026, 8:05 pm
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a constant currency(2) basis. Excluding the impact of the Company’s previously announced strategic exits of GI product offerings, net sales increased 6.0% on an organic cons
- Massive Bio and QC Healthcare Announce National Collaboration to Transform Cancer Patient Access29 July 2026, 2:00 pm
BOCA RATON, Fla. & CHARLOTTE, N.C. & ATLANTA--(BUSINESS WIRE)--Massive Bio, Inc., a leader in AI-enabled oncology clinical trial matching and patient navigation, and QC Healthcare, LLC, a nationwide company focused on telehealth, clinical research, pharmacy services, artificial intelligence, healthcare analytics, and population health, today announced a strategic collaboration to fundamentally reshape how cancer patients access clinical trials, coordinated care, and telehealth support throughou
- NeoGenomics Reports Second Quarter 2026 Results28 July 2026, 8:05 pm
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.
- Florida Schools Invited to Participate in Math Study from UF Lastinger Center and Kiddom28 July 2026, 1:30 pm
GAINESVILLE, Fla.--(BUSINESS WIRE)--Kiddom and the University of Florida Lastinger Center announced a research partnership studying if and how embedding professional learning at a teacher's precise point-of-need impacts instruction and student outcomes in middle school math.Kiddom built Florida's B.E.S.T.-aligned math curriculum to give teachers their core instructional materials, assessments, and insights in one coherent system. This partnership goes further, weaving Lastinger Center's instruct
- Greenspace Health Launches ‘Momentum’ to Help Advance the Future of Measurement-Based Care28 July 2026, 12:46 pm
ST. AUGUSTINE, Fla.--(BUSINESS WIRE)-- #MBC--Greenspace Health, a leader in Measurement-Based Care (MBC) technology for behavioral health, has launched Momentum, a new industry publication created to help behavioral health leaders navigate the growing shift toward outcomes-focused, value-based care. Featuring research, real-world case studies and practical implementation strategies, Momentum provides evidence-informed insights into the clinical, operational and economic impact of Measurement-Based Car
- Massive Bio and GELL Announce Strategic Partnership to Advance Research, Medical Education, and Artificial Intelligence Across Latin America and the United States27 July 2026, 2:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin American Study Group on Lymphoproliferative Disorders (GELL), one of the most influential scientific and academic networks dedicated to lymphomas and hematologic malignancies in Latin America, today announced a strategic partnership focused on advancing clinical research, physician education, and innovation throu
- Sugar Sands Publishing LLC Announced Publication of a Highly Anticipated AI Safety Standards Suite27 July 2026, 11:00 am
PENSACOLA, Fla.--(BUSINESS WIRE)--Sugar Sands Publishing LLC today announced the formal constitution of the independent Cognitive Mode Operating System Standards Board (CMOS-SB) and launch of a governance framework for how AI systems interact with human emotion and cognition. THE GOVERNANCE GAP AI systems are increasingly being used in enterprise, health care, education and public infrastructure, where they can read emotional cues, respond to cognitive patterns and influence how people relate t
- SurGenTec® Secures FDA Clearance for ION-L™ - Lumbar Navigation Compatible24 July 2026, 3:10 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #FDAClearance--SurGenTec®, a medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its ION-L™ navigation instruments for use with the ION-L™ Lumbar Facet Fixation System. The system is engineered for compatibility with Medtronic's StealthStation™ navigation platform, enabling enhanced precision during posterior lumbar facet fusion proced
- Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 202623 July 2026, 8:05 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clinical and operational progress. “The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningf
- Thyora Therapeutics Launches to Build a Next-Generation Platform for Covalent Drug Discovery23 July 2026, 6:00 pm
TAMPA, Fla.--(BUSINESS WIRE)-- #biotech--Thyora Therapeutics today emerged from stealth as a biotechnology company leveraging next-generation covalent chemistry, with a mission to accelerate clinical translation and create therapies for high-unmet medical needs. Founded on breakthrough discoveries published today in Science by scientists at Moffitt Cancer Center, the company is advancing an integrated platform that combines novel covalent chemistry with AI-enabled chemoproteomics to unlock a new generatio
- Los Angeles County Department of Public Health and OpenEvidence Partner to Connect Physicians With Local Public Health Guidance23 July 2026, 1:00 pm
MIAMI & LOS ANGELES--(BUSINESS WIRE)-- #ClinicalAI--The Los Angeles County Department of Public Health (DPH) and OpenEvidence, an AI-powered clinical decision support platform, today announced a collaboration to help physicians quickly find official LA County Public Health resources when searching for clinical information. Under this new partnership, when physicians in LA County search the platform for selected public health topics, OpenEvidence will display related LA-specific messages from Public Health. T
- Avanti Capital Expands Philanthropic Mission as The Foundation Establishes U.S. Presence23 July 2026, 4:00 am
BOCA GRANDE, Fla.--(BUSINESS WIRE)--Avanti Capital establishes The Foundation in the U.S., advancing a multigenerational philanthropic legacy focused on research, education and impact.
- Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer22 July 2026, 8:30 pm
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne
- Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer22 July 2026, 8:30 pm
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne
- ReturnPro Releases “The GLP-1 Effect” Report Showing Significant Changes in GLP-1 Users’ Shopping Patterns and Returns Behaviors22 July 2026, 1:01 pm
MIAMI--(BUSINESS WIRE)--ReturnPro, the industry leader in returns management and reverse logistics, today announced findings from its new consumer study examining the effects of GLP-1 medications and how they are quietly reshaping what consumers are buying, returning, holding onto and wishing retailers would do differently to address their unique needs. The GLP-1 Effect report surveyed 500 U.S. adults currently taking, or who have taken within the past 12 months, a GLP-1 medication (Ozempic, We
- Cancer Cell Diagnostics (CCDx) Debuts Whole-Cell Genomic Profiling to Redefine Liquid Biopsy22 July 2026, 1:00 pm
JUPITER, Fla.--(BUSINESS WIRE)--Cancer Cell Diagnostics today announced the commercial launch of its CellSight™ DNA comprehensive genomic profiling test. This test is built on a fundamentally distinct source material from conventional liquid biopsy. Most blood-based cancer tests analyze cell-free circulating tumor DNA, the short, degraded fragments that tumors shed into the bloodstream. CCDx utilizes a different approach. The CellSight™ platform uses a proprietary, patent-pending enrichment met
- CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula22 July 2026, 11:00 am
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform (“dV5”). Alongside its existing indication for Intuitive 8 mm round cannulas, the AirSeal Robotic Solution now has an expanded indication for use across Intuitive’s portfolio of da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems. Building on the existing indication for I
- Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study22 July 2026, 10:30 am
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. Ivonescimab plus platinum-doublet chemotherapy in this trial continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone. The HARMONi
- Vasomune Therapeutics to Present on Vascular Leak in Combat-Relevant Injury at the 2026 Military Health System Research Symposium21 July 2026, 11:45 pm
TORONTO--(BUSINESS WIRE)-- #ARDS--Dr. Harold Kim, Chief Scientific Officer, will present at the 2026 Military Health System Research Symposium (MHSRS), DOW's premier scientific meeting
- Redwire Opens State-of-the-Art Facility in Indiana to Accelerate Space-Enabled R&D and Manufacturing with a Focus on Next-Gen Drug Development and Human Health Breakthroughs21 July 2026, 11:00 am
JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, has opened its new 30,000 square foot state-of-the-art, vertically-integrated research and microgravity payload development facility in Georgetown, Indiana. The facility will serve as a global hub supporting accelerated demand as the company continues to expand its leadership in space-enabled research, development, and manufacturing with a focus on pharmaceutical/biot
- NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS20 July 2026, 9:23 pm
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
- Massive Bio Partners With FOMAT to Expand Cancer Patient Prescreening for Clinical Trial Access20 July 2026, 4:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio partners with FOMAT, the largest U.S. Embedded Research Organization, to launch AI-powered cancer patient prescreening for clinical trials
- Kalogon Launches Verro, a New Medicare-coded Custom Wheelchair Cushion Built for the Most Complex Support Needs20 July 2026, 2:00 pm
MELBOURNE, Fla.--(BUSINESS WIRE)--Kalogon expands its seating line with Verro, a Medicare-coded custom cushion engineered for wheelchair users with complex postural needs.
- Precision IO Group to Present Epione® Robotic Platform and Remote Intervention Program at Society of Robotic Surgery Annual Meeting20 July 2026, 12:50 pm
MIAMI--(BUSINESS WIRE)--Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will present at the Society of Robotic Surgery (SRS) Annual Meeting in Hollywood, Florida, July 22–26, 2026, on booth #325. At the meeting, interventional radiology leaders Prof. Dr. Sean Tutton, MD, Professor of Radiology and Orthopedics, and Dr. Govindarajan Narayanan, MD, FSIR, Professor of Radiology and Chief of Interventional Oncology and the first physician to treat a patient with Epion
- CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting20 July 2026, 11:00 am
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL. During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdomi
- Sun Nuclear to Showcase Next-Generation Innovations at AAPM & COMP 2026 Annual Meeting17 July 2026, 12:30 pm
MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, announced today the featured innovations in quality assurance (QA) for machine oversight and adaptive radiotherapy, as well as AI-assisted treatment planning, to be shown at the 2026 AAPM & COMP Annual Meeting, July 19–21 in Vancouver. Centered on the theme of Next-Gen Innovations for Next-Level Physics, the Sun Nuclear exhibit reflects a focus on smart, practical tools that support medical physics teams to operate wit
- Boston Children’s Hospital and OpenEvidence Collaborate to Advance AI-Powered Analysis of Clinical Practice Patterns16 July 2026, 1:00 pm
MIAMI & BOSTON--(BUSINESS WIRE)-- #medicalAI--Boston Children's Hospital, one of the nation's top pediatric hospitals, and OpenEvidence, the leading AI-powered clinical decision support platform, today announced a multi-year collaboration to examine how clinicians' real-world use of AI tools at the point of care relates to practice patterns and delivery of care. OpenEvidence has seen broad adoption in clinical settings, yet little is known about how that adoption relates to clinical practice patterns at a p
- Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 202616 July 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on Thursday, July 23, 2026. The call is scheduled to take place at 4:30 p.m. EDT. The live and archived webcast can be accessed through the Investor Information section of the company’s website, www.smmttx.com. About Summit Therapeutics Inc. Summit Therapeutics Inc. is a biopharmaceutical oncology company
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results15 July 2026, 8:30 pm
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2026. Financial Results Revenue The revenues for the second quarter of fiscal 2026 were $7.8 million compared to $7.9 million for the second quarter of fiscal 2025, a 2% decrease. The revenues for the second quarter of fiscal 2026 consisted of $7.7
- Paley Institute Advances the Future of Stature Surgery with Next-Generation Internal Lengthening Technology15 July 2026, 10:00 am
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--The Paley Orthopedic & Spine Institute (Paley Institute), the world's leading center for stature surgery, achieves another historic milestone with the first completed stature surgery utilizing the latest FDA-approved PRECICE Max (PMAX) nail. As the exclusive global launch center for the technology, Paley Institute continues to lead the evolution of modern stature surgery – an advanced application of limb lengthening science pioneered over decades of o
- American Ocean Minerals Highlights Moana Minerals AUV Survey Capturing More Than 600,000 Seafloor Images in the Cook Islands14 July 2026, 12:30 pm
TAMPA, Fla. & RAROTONGA, Cook Islands--(BUSINESS WIRE)--American Ocean Minerals Corporation ("AOMC"), which is building a responsible supply of critical minerals and rare earth elements through its previously announced merger with Odyssey Marine Exploration (NASDAQ: OMEX), today highlighted Moana Minerals Ltd.'s ("Moana Minerals" or "MML") completion of a high-definition autonomous underwater vehicle seafloor survey within its Exploration License 3 (“EL3”) area in the Cook Islands Exclusive Eco
- Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.14 July 2026, 11:00 am
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent unmet medical needs. Previously, ridinilazole was evaluated in Summit’s Phase III Ri-CoDIFy study for the tre
- Massive Bio Announces Partnership with Sequence Me Now to Help Cancer Patients Access Clinical Trials13 July 2026, 2:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a technology company that uses artificial intelligence to help cancer patients identify clinical trials for which they may be eligible, today announced a new partnership with Sequence Me Now (SMN), a nonprofit patient advocacy organization dedicated to helping cancer patients access genomic sequencing and personalized medicine. Through the partnership, Massive Bio is featured on the "Find a Trial" page of Sequence Me Now's website, the fourth step
- OpenEvidence and NewYork-Presbyterian, Columbia University and Weill Cornell Medicine Expand Clinical AI Tools Across New York City and Westchester9 July 2026, 3:00 pm
MIAMI & NEW YORK--(BUSINESS WIRE)-- #MedicalAI--OpenEvidence, a medical AI and clinical decision support tool for U.S. clinicians, today announced a collaboration with NewYork-Presbyterian and its affiliated medical schools, Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine, to deploy OpenEvidence across all hospitals and care sites throughout the Greater New York region. This enterprise-scale collaboration will place trusted, evidence-based clinical AI in the hands o
- NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer9 July 2026, 11:05 am
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
- OpenEvidence, Anticoagulation Forum Partner to Expand Access to AI-Enabled Guidance in Antithrombotic Care8 July 2026, 4:00 pm
MIAMI & BOSTON--(BUSINESS WIRE)--OpenEvidence and the Anticoagulation Forum (AC Forum) today announced a strategic partnership to provide antithrombotic guidance and tools that support decision-making in clinical practice. By combining the AC Forum’s leadership in education and multidisciplinary clinical guidance with OpenEvidence’s advanced artificial intelligence platform, clinicians will gain access to timely and practical evidence in antithrombotic therapy. “Clinicians are increasingly turn
- Former Merck and NASA Leaders Bring Strategic Expertise to SpaceMD Amid Rising Demand for its In-Space Pharmaceutical Development Capabilities8 July 2026, 11:00 am
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, announced today it has appointed pioneering industry leaders Paul Reichert, former Principal Investigator at Merck Research Laboratories, and Niki Werkheiser, former Director of Technology Maturation at NASA’s Space Technology Mission Directorate, to serve in strategic advisory roles at Space Microgravity Development LLC (SpaceMD), Redwire’s venture company focuse
- Pangea Pharmaceuticals Advances Its Next Phase of Growth With an Expanding Commercial Portfolio7 July 2026, 2:13 pm
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the next phase of its growth strategy, marked by an expanding portfolio of therapies, growing commercialization capabilities, and continued investment in its pharmaceutical platform. The milestone reflects Pangea's evolution into a scalable pharmaceutical organization focused on identifyi
- Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of MCO-0107 July 2026, 1:00 pm
TAMPA, Fla. & DALLAS--(BUSINESS WIRE)--Catalent & Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010
- DemeRx Strengthens Leadership Team With Appointment of Biopharmaceutical Executive Michael Snitkovsky as Chief Operations Officer7 July 2026, 11:45 am
MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced the appointment of Michael Snitkovsky as chief operations officer, adding a seasoned biopharmaceutical executive with more than 20 years of experience advancing therapies from preclinical research through clinical development. Mr. Snitkovsky is recognized for his strategic leadership, operational rigor, and ability to unite cross‑functional and globa
- NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 20267 July 2026, 11:05 am
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.
- Coral Connect Acquires AdvisorWoRx, Names Founder Edie Gigot President of Infusion Services6 July 2026, 11:19 pm
CORAL SPRINGS, Fla.--(BUSINESS WIRE)--Coral Connect, LLC announced it has acquired AdvisorWoRx, LLC, the strategic healthcare consulting firm founded and led by Edie Gigot, MSN-RN, MBA. Coral is a specialty infusion enablement platform that helps healthcare operators improve their purchasing decisions, operate leaner, and get reimbursed more across every site of care. Gigot joins Coral's executive leadership team as President of Infusion Services, leading the company's clinical operations, phar
- OSSIO Raises the Bar for Sports Medicine at Specialty’s Major Meeting6 July 2026, 1:15 pm
TAMPA, Fla.--(BUSINESS WIRE)-- #AOSSM--OSSIO Inc., a fast-growing medical technology platform company focused on advancing orthopedic surgery with bio-integrative, metal-free fixation implants, today confirmed its slate of activities and announcements planned for the upcoming American Orthopaedic Society for Sports Medicine (AOSSM) 2026 annual meeting at the Seattle Convention Center July 8–11. Update on study of KneeBar Procedure. Interim results from the multicenter, 50-patient clinical study of the c
- CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 20262 July 2026, 8:05 pm
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro
- MuseCell Innovations Enters U.S. Market, Bringing Restorative Stem Cell Therapy Directly to American Patients1 July 2026, 1:00 pm
SINGAPORE--(BUSINESS WIRE)--MuseCell Innovations launches world's only clinically validated stem cell platform in the US for disease treatment, performance, and aesthetics.
- Men’s Health Month: Putting Sexual Wellness in the Spotlight30 June 2026, 1:30 pm
MIAMI--(BUSINESS WIRE)--Men’s Health Month serves as an important reminder that sexual wellness is a fundamental component of overall well-being, yet it is often overlooked in conversations about men’s health. While discussions frequently focus on fitness, mental health, and preventive care, sexual health plays an equally vital role in a man’s quality of life, confidence, and relationships. Prioritizing protection is an important part of maintaining sexual wellness, empowering men to take an ac
- Humata Health Expands Reach of Prior Authorization Technology to Independent Practices, Regional Health Centers and Specialty Clinics30 June 2026, 1:00 pm
WINTER PARK, Fla.--(BUSINESS WIRE)--Humata Health, the leader in AI-powered medical review technology, today announced a new standalone prior authorization platform built for independent practices, regional health centers and specialty clinics. The denial reduction tool analyzes clinical documentation against applicable payer policies before submission and returns a real-time score, identifying gaps in the record that may trigger a denial while reducing time spent on preparation. It also featur
- AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts29 June 2026, 6:53 pm
TALLAHASSEE, Fla.--(BUSINESS WIRE)-- #AHFcares--AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts
- OpenEvidence and Journal of Medical Insight (JOMI) Partner to Bring Peer-Reviewed Surgical Videos to Clinicians25 June 2026, 4:00 pm
MIAMI & BOSTON--(BUSINESS WIRE)--The Journal of Medical Insight’s peer-reviewed surgical video library is now part of OpenEvidence.
- ReliaQuest Invests $1.5 Million to Advance AI and Cybersecurity Education at the University of South Florida25 June 2026, 1:30 pm
TAMPA, Fla.--(BUSINESS WIRE)--ReliaQuest today announced a $1.5 million investment to expand AI cybersecurity research and education at the University of South Florida’s College of Artificial Intelligence, Cybersecurity and Computing. The gift will establish the college’s first-ever endowed professorship and create a new study track within the ReliaQuest Labs program focused on artificial intelligence-supported software engineering. “Cybersecurity is the greatest technical challenge of our gene
- NeoGenomics Appoints Carolyn Starrett to its Board of Directors25 June 2026, 11:05 am
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.
- OSSIO Inc.’s Distribution Deal With OrthoPediatrics Corp. Brings Bio-Integrative, Metal-Free OSSIOfiber® Implants to U.S. Children’s Hospitals Nationwide24 June 2026, 4:00 pm
TAMPA, Fla.--(BUSINESS WIRE)-- #medicaldevice--In striking an exclusive distribution agreement with OrthoPediatrics Corp. announced today, OSSIO Inc. expands access to its revolutionary orthopedic fixation technology — bio-integrative, metal-free OSSIOfiber® implants — to the approximately 400 U.S. children’s hospitals and care facilities whose orthopedic surgeons treat most pediatric patients admitted with bone fractures and skeletal deformities. "It’s not often that kids need implants for broken bones, since
- American Ocean Minerals Announces Successful Completion of MV Anuanua Moana Expedition 7, Advancing Deep-Sea Environmental Baseline Research in the Cook Islands24 June 2026, 1:00 pm
TAMPA, Fla.--(BUSINESS WIRE)--Today, American Ocean Minerals Corporation (AOMC) announced the successful completion of Expedition 7, a research campaign designed to support the environmental baseline studies required for future deep-sea mineral exploration and development activities in the Cook Islands. Expedition 7 was conducted over approximately three weeks aboard the MV Anuanua Moana, a proprietary research vessel advancing critical deep-sea environmental and exploration programs across its
- ModMed Scribe 2.0 Surpasses One Million AI-Powered Patient Visits24 June 2026, 12:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--ModMed®, a leading provider of software and services to specialty medical practices, today announced that its AI-powered clinical documentation solution, ModMed Scribe 2.0, has been used in more than 1,000,000 patient visits. The explosive growth was driven by a 300% growth rate in usage that climbed from 240,000 visits in March to over 1 million just three months later. ModMed Scribe delivers immediate and dramatic results for clinicians across the specialtie
- SNO and OpenEvidence Launch Official Generative AI Partnership23 June 2026, 4:00 pm
MIAMI & HOUSTON--(BUSINESS WIRE)--The Society for Neuro-Oncology (SNO), the world's largest multidisciplinary organization dedicated to advancing research, education, and clinical care for patients with brain and spinal cord tumors, and OpenEvidence, the leading AI-powered clinical decision support platform, today announced a landmark partnership, designating OpenEvidence as SNO's official generative AI partner. As part of the collaboration, SNO will embed OpenEvidence across its member-facing
- Akumin and CGS Premier Launch Mobile Healthcare Innovations to Scale Akumin AXIS® Portfolio of Relocatable Clinics23 June 2026, 2:00 pm
TAMPA, Fla.--(BUSINESS WIRE)-- #Akumin--Akumin Inc. (“Akumin” or the “Company”), a leading provider of diagnostic imaging and oncology solutions, has announced the formation of Mobile Healthcare Innovations (MHI), a joint venture partnership with Wisconsin based manufacturer CGS Premier, to engineer, assemble and deploy Akumin AXIS® relocatable clinics to meet growing U.S. demand. Leaders cut the ribbon on a new 85,400-square-foot facility in New Berlin, Wisconsin, purposefully built in size and structur
- NationsBenefits Redefines Access Through National Expansion of Integrated Wellness, OTC, and Nutrition Benefits23 June 2026, 11:00 am
PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--Eligible health plan members can now use the NationsBenefits® Flex Card at Sam’s Club to simplify grocery, OTC, and health and wellness purchases.
- The Cataltheia Group and Bruno Vision Care Announce Publication of Landmark Clinical Study Validating Deseyne® Extended Depth of Focus Technology for Presbyopia22 June 2026, 12:07 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #ClinicalResearch--New study in Optometry and Vision Science validates Bruno Vision Care's Deseyne® EDOF lens technology, expanding options for presbyopia correction.
- Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD22 June 2026, 12:00 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, announced today that it will present new clinical data and research updates at Cure SMA’s Annual SMA Research & Clinical Care Meeting being held June 24-26, 2026, in Orlando,
- CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer17 June 2026, 8:35 pm
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. “We are pleased to welcome a talented and experienced financial executive of John’s caliber to CONMED,” said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “John brings deep healthcare and
- NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes17 June 2026, 10:00 am
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
- AHF Welcomes Lula–Tedros Call for Equity in Pandemic Agreement, Warns against Rushing Empty Deal16 June 2026, 2:37 pm
MIAMI, GENEVA & SÃO PAULO--(BUSINESS WIRE)-- #Brazil--The AIDS Healthcare Foundation (AHF) and the AHF Global Public Health Institute welcome the open letter issued by President Luiz Inácio Lula da Silva of Brazil and World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus on the occasion of the G7 Summit, calling on the leaders of the G7, G20, BRICS, and all nations to finish the Pathogen Access and Benefit-Sharing (PABS) annex of the WHO Pandemic Agreement. AHF particularly commends t
- Humanetics Corporation Selected for Oral Presentation at 2026 Military Health System Research Symposium16 June 2026, 1:05 pm
MINNEAPOLIS--(BUSINESS WIRE)--HUMANETICS CORPORATION SELECTED FOR ORAL PRESENTATION AT 2026 MILITARY HEALTH SYSTEM RESEARCH SYMPOSIUM
- LaVoie’s LHS Fifteen-Slide Presentation® for 2026: Make Your Science Stick in the AI Era Returns to BIO 202616 June 2026, 12:37 pm
BOSTON & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #BIO2026--The LHS Fifteen-Slide Presentation® returns to BIO 2026 with new AI-era strategies for building investor-ready biotech stories.
- TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale16 June 2026, 12:30 pm
JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production. The launch addresses a long-standing pain point for RNA therapeutics develo
- Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services16 June 2026, 12:00 pm
TAMPA, Fla.--(BUSINESS WIRE)--Catalent announces the launch of Qai, an enterprise AI tool designed to elevate the best quality systems and processes across Catalent’s network.
- NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes15 June 2026, 9:24 pm
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
- SurGenTec® Receives FDA Clearance for ION-L™, a Novel Lumbar Facet Fixation System Representing a Paradigm Shift in Minimally Invasive Spine Surgery15 June 2026, 4:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #FDAClearance--SurGenTec®, a medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced FDA clearance of its ION-L™ Lumbar Facet Fixation System. ION-L™, part of SurGenTec's facet fixation platform, is indicated for the treatment of patients with degenerative disc disease (DDD) from L3 to S1 in skeletally mature patients who have failed conservative care. This clearance is supported by compelling long-term clinical evidenc
- Klick Labs Announces Vocal Biomarker Research Collaboration15 June 2026, 12:29 pm
TORONTO & NEW YORK--(BUSINESS WIRE)-- #AppliedSciences--Researchers at Klick Labs are launching a series of clinical studies with Mayo Clinic in Florida exploring the use of novel vocal biomarkers.
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida15 June 2026, 10:00 am
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billion in Jacksonville, Florida to strengthen its Vision operations by scaling U.S.-based manufacturing, packaging and distribution capabilities. The investment includes construction of a new, state-of-the-art distribution facility, alongside advanced manufacturing and packaging technologies to exp
- Walgreens Helps FIFA World Cup™ Fans in Miami Stay Game-Ready with Pharmacy Care and Everyday Essentials11 June 2026, 4:00 pm
DEERFIELD, Ill.--(BUSINESS WIRE)--As millions of fans travel to FIFA World Cup 2026™ matches in the U.S. this summer, Walgreens is making it easier to stay prepared, energized and healthy with convenient access to game-day essentials and trusted pharmacy services. Whether heading to the stadium or wrapping up a late match, Walgreens offers fans in Miami a one-stop destination for official licensed products of the FIFA World Cup 26™ and necessities like water, snacks, sunscreen, over-the-counter
- Paysafe and Skrill Get on Board With Woody & Kleiny’s Outrageous US Soccer Road Trip: 39 Days, 15,000 Miles, Streamed Live 24/711 June 2026, 1:00 pm
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Paysafe (NYSE: PSFE), a global payments platform, is taking its technology to the heart of America’s biggest soccer summer, fueling a 39-day, 15,000-mile streamed road trip powered by viral creators Woody & Kleiny. Known as the ‘In A State’ tour, this record-breaking journey streams live on Kick and TikTok from June 11, as Woody & Kleiny tear through major cities including Los Angeles, Arlington, Boston and East Rutherford, engaging soccer fans and s
- ERMA Systems Named to MM+M's 2026 Agency Partners Power List for AI Health Platforms11 June 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)--ERMA Systems, the AI-powered Medical, Legal, and Regulatory (MLR) review platform built specifically for life sciences organizations, today announced its inclusion on the 2026 Agency Partners Power List published by MM+M, one of the healthcare industry's leading publications. The recognition highlights organizations shaping the future of healthcare commercialization and innovation. ERMA was recognized in the AI Health Platforms category for its transformative approach to
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients11 June 2026, 11:45 am
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is an extended depth of focus (EDOF) lens designed to support visual clarity and quality for patients undergoing cataract surgery.3 Benefits of TECNIS PureSee IOL: Range of vision: Excellent distance and intermediate vision with some near vision3* Low level of bothersome visual symptoms: 97% of p
- DermaSensor Announces Class IIb CE Mark and Collaboration with NHS, Marking the Beginning of Its Global Expansion10 June 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)--DermaSensor, a health technology company transforming skin cancer detection with AI-powered technology, today announced it has received Class IIb CE Mark for the DermaSensor device, enabling commercialization across the European Economic Area (EEA) and marking the beginning of the company’s global expansion strategy. The CE Mark demonstrates that DermaSensor meets European Union standards for safety, health, and environmental protection and paves the way for broader inte
- Summit Therapeutics Announces Proposed Public Offering of Common Stock9 June 2026, 8:47 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price, less underwriting discounts and c
- OpenEvidence and the American Academy of Ophthalmology Partner to Close the Gap Between Evidence and Eye Care9 June 2026, 4:00 pm
MIAMI & SAN FRANCISCO--(BUSINESS WIRE)-- #ClinicalAI--The American Academy of Ophthalmology, the world’s largest association of eye physicians and surgeons, and OpenEvidence, the most widely used medical AI platform among U.S. physicians, today announced a strategic partnership to integrate the Academy’s Preferred Practice Patterns® and Ophthalmic Technology Assessments directly into the OpenEvidence platform. The partnership makes the Academy’s authoritative ophthalmology guidance available alongside the br
- Shields Health Solutions Brings Integrated Specialty Pharmacy Services to Baptist Health in Jacksonville9 June 2026, 12:00 pm
STOUGHTON, Mass. & JACKSONVILLE, Fla.--(BUSINESS WIRE)--Shields Health Solutions Brings Integrated Specialty Pharmacy Services to Baptist Health in Jacksonville
- Alesis LLC Adds Three New Joint Ventures in a Single Week, Expanding the Alesis Apnea Network to Chicago, Upper Michigan, and South Florida8 June 2026, 6:32 pm
COCOA BEACH, Fla.--(BUSINESS WIRE)--Alesis LLC today announced the addition of three new joint venture locations to the Alesis Apnea Network in a single week: the TMJ & Sleep Therapy Centre of Chicago in St. Charles, Illinois; Alpha Omega Dental Center in Marquette, Michigan; and South Florida Food Allergy Center in Boca Raton, Florida. Together, the additions bring the Alesis Apnea Network to a total of five joint venture locations across five states, connecting patients who suffer from ob
- Republic Bank Brings Community Together for Sixth Annual Juneteenth Celebration8 June 2026, 4:00 pm
LOUISVILLE, Ky.--(BUSINESS WIRE)--This past Saturday, Republic Bank & Trust Company (“Republic” or the “Bank”) hosted its sixth annual Juneteenth celebration at the Republic Bank Foundation YMCA, bringing together community members for a day centered on wellness, education, and culture. The event created a vibrant, welcoming atmosphere where attendees danced, explored local vendor booths, and enjoyed food from businesses proudly operated by Black and women entrepreneurs. “At Republic Bank,
- Xenix Medical Announces FDA Clearance and Full Commercial Launch of the Lux™ Expandable Lumbar Interbody Fusion System8 June 2026, 2:30 pm
ORLANDO, Fla.--(BUSINESS WIRE)-- #InterbodyFusion--Xenix Medical Announces FDA Clearance and Full Commercial Launch of Its Lux Expandable Interbody Fusion System
- Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference4 June 2026, 8:30 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab. The presentatio
- Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings4 June 2026, 6:15 pm
BOCA RATON, Fla. & STOCKHOLM--(BUSINESS WIRE)-- #DrivenbyPurpose--Vycellix to attend key upcoming investor & partnering events to share progress reports for its allogeneic cancer cell therapy platforms and products.
- Kalogon Raises $5.75M to Make Sitting Healthier for All4 June 2026, 1:00 pm
MELBOURNE, Fla.--(BUSINESS WIRE)--Kalogon raises $5.75M led by Enable Ventures to expand smart seating solutions for wheelchair users, aviation and beyond.
- Humata Health Joins CMS Electronic Prior Authorization Acceleration Initiative to Speed Care for Patients and Providers4 June 2026, 1:00 pm
WINTER PARK, Fla.--(BUSINESS WIRE)--Humata Health, the leader in AI-powered medical review technology, today announced it has joined the Centers for Medicare and Medicaid Services (CMS) Electronic Prior Authorization Acceleration initiative as a Friend of the Ecosystem. Launched through the CMS Health Tech Ecosystem, it brings together health systems, payers, electronic health record developers, and technology partners to address the workflow, technical, and operational challenges slowing adopt
- GE HealthCare receives FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, advancing AI-enabled radiation therapy planning with expanded clinical capabilities4 June 2026, 12:00 pm
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for MIM Contour ProtégéAI+™ 2.0, an AI-enabled auto-contouring software to assist radiation oncology care teams with treatment planning. This can help clinicians reduce treatment planning time, enabling them to focus on delivering more timely and personalized care for patients. The FDA clearance includes a Predetermined Change Control
- Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting4 June 2026, 12:00 pm
DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting
- Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting4 June 2026, 11:00 am
NEW YORK--(BUSINESS WIRE)--Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally. Today, the Company presented results from several clinical and preclinical studies that support the initiation of Phase 3 studies of elismetrep, a novel TRPM8 channel blocker. Elismetrep is a potentially new approach for migraine and the only agent known to be in late-stage deve
- Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology3 June 2026, 8:30 pm
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology
- Massive Bio and Optellum Collaborate to Accelerate Clinical Trial Access for Early-Stage Non-Small Cell Lung Cancer Patients3 June 2026, 2:01 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and Optellum, the leader in AI-enabled lung cancer diagnosis and the developer of the world’s first FDA-cleared clinical decision support software for early-stage lung cancer, today announced a collaboration to bridge early lung cancer detection with clinical trial access for patients with non-small cell lung cancer (NSCLC). The collaboratio
- HSS Chief of Sports Medicine, Riley J. Williams III, MD, Named FIFA Venue Medical Officer for the 2026 World Cup3 June 2026, 2:00 pm
NEW YORK--(BUSINESS WIRE)--FIFA World Cup 26™ has named Hospital for Special Surgery (HSS), ranked No. 1 in orthopedics nationally by U.S. News & World Report (2024–2025), Sports Medicine Surgeon, Riley J. Williams III, MD, as Venue Medical Officer (VMO) for the 2026 World Cup. The New York / New Jersey area will host matches, including the final, taking place in East Rutherford, New Jersey at MetLife Stadium. In this role, Dr. Williams, Chief of the HSS Sports Medicine Institute, Medical D
- STARLIMS Appoints Max Schultz as Chief Executive Officer3 June 2026, 1:36 pm
HOLLYWOOD, Fla.--(BUSINESS WIRE)--STARLIMS, a global leader in enterprise laboratory informatics software, today announced the appointment of Max Schultz as Chief Executive Officer. This leadership transition comes at a time of growth for STARLIMS, with the company accelerating product innovation, expanding its portfolio through strategic acquisitions, and delivering agentic capabilities for enterprise laboratories. As a seasoned enterprise software executive, Schultz brings a strong track reco
- Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference3 June 2026, 12:01 pm
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June 8-10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 pm ET on Tuesday, June 9, during which he will provide an update on the Com
- Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 20262 June 2026, 8:01 pm
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Xenix Medical Announces FDA Clearance and Full Commercial Launch of the Riva Posterior Fixation System®2 June 2026, 5:22 pm
ORLANDO, Fla.--(BUSINESS WIRE)-- #MedicalDevices--Xenix Medical announces FDA clearance and full commercial launch for its Riva Posterior Fixation System.
- eternalHealth, Zynix AI, and nirvanaHealth Announce Integrated Partnership to Scale AI-Enabled Care Management and Member Engagement2 June 2026, 2:00 pm
BOSTON & TAMPA, Fla.--(BUSINESS WIRE)--eternalHealth, a Medicare Advantage plan serving Medicare beneficiaries in Massachusetts and Arizona, today announced an integrated partnership with Zynix AI, a healthcare AI platform built to operationalize care management, patient engagement, and quality improvement at scale, and nirvanaHealth, a cloud-native enterprise platform supporting pharmacy benefit management, claims adjudication, and centralized healthcare data infrastructure. Since January 1, 2
- Neuropacs Announces the Publication of a New Study Comparing the First‑of‑Its‑Kind FDA De Novo–Classified Imaging Biomarker for Parkinson’s Disease with CSF Alpha‑Synuclein Seed Amplification Assay2 June 2026, 11:00 am
GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp., a leader in AI‑powered neurodiagnostics, today announced the publication of a seminal study co-authored by David Vaillancourt, PhD, the company’s Co‑Founder and Chief Scientific Officer. The research published in Annals of Neurology reveals a positive alpha-synuclein (α-synuclein) seed amplification assay (SAA) and the automated imaging differentiation for parkinsonism (AIDP) provide unique information key to understanding Parkinson’s diseas
- Sarepta Therapeutics to Participate in Upcoming Investor Conferences1 June 2026, 8:30 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club i
- Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research1 June 2026, 8:00 pm
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of twelve research grants to universities under the company’s fifteenth Annual Research Award Program. “Research and clinical evidence continue to be at the core of
- Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China31 May 2026, 1:06 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit’s partner Akeso, Inc. (HKEX Code: 9926.HK), will be presented today as part of the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation is entitled “Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untrea
- Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 202630 May 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) co-sponsored by Summit and Akeso, featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. The data were presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation, entitle
- AHF: Florida Lawmakers Reverse HIV Drug Cuts, Restoring Coverage for Thousands29 May 2026, 6:30 pm
TALLAHASSEE, Fla.--(BUSINESS WIRE)--Thousands of Floridians living with HIV will keep the medication that keeps them alive, after the Florida Legislature today passed a state budget that reverses this year's cuts to the AIDS Drug Assistance Program (ADAP). The budget returns eligibility to 400 percent of the federal poverty level, brings back the medications the Department of Health had dropped, including Biktarvy, funds the program with $75 million, and adds independent oversight. "This is wha
- SurGenTec Secures FDA Clearance for ION-C™ - Now Navigation Compatible29 May 2026, 4:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #CervicalSpine--SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its ION-C™ navigation instruments for use with the ION-C™ posterior cervical facet fixation implant. The system is engineered for comp
- Massive Bio Partners with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to Expand Cancer Patients' Access to Clinical Trials29 May 2026, 2:14 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global precision oncology company, today announced a new partnership with TOUCH, The Black Breast Cancer Alliance (TOUCH BBCA), a breast cancer patient advocacy organization, and Navigating Trials, a clinical trial navigation platform serving patients across all cancer types. Through this collaboration, Massive Bio's AI-powered trial matching will be made available directly within both organizations' digital platforms, giving their patient commu
- Veradermics to Present at Upcoming June Investor Conferences28 May 2026, 8:30 pm
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 3 in New York, NY Reid Waldman, M.D., Chief Executive Officer of Veradermics, and Mark Neumann, Chief Commercial
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June28 May 2026, 8:01 pm
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investo
- Tallahassee Memorial HealthCare and Inspirity Health Partners Launch Strategic Supply Chain Partnership28 May 2026, 1:00 pm
ROCHESTER, Minn.--(BUSINESS WIRE)--Inspirity Health Partners (IHP) has entered into a strategic, multi-year agreement with Tallahassee Memorial HealthCare (TMH) to advance and integrate TMH’s supply chain capabilities through a collaborative, high-performance partnership model. With a well-established category management structure, disciplined operational processes and strong clinical engagement, TMH joins Inspirity from a position of strength. Through this new collaboration, TMH will expand it
- Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences28 May 2026, 11:00 am
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside ch
- Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 202627 May 2026, 8:05 pm
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences’ Management is scheduled to present on Wednesday, June 10, at 10:00 am ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presentat
- Alesis LLC Expands to the Pacific Northwest With Dr. Lyly Fisher — First Seattle-Area Provider of Alesis OSA1™27 May 2026, 6:41 pm
COCOA BEACH, Fla. & SEATTLE--(BUSINESS WIRE)--Alesis LLC, the U.S. distributor of the Alesis OSA1™ medical device, today announced a joint venture partnership with Dr. Lyly Fisher, DDS, Diplomate, ABDSM, ASBA -- a dual board-certified sleep dentist with offices in Seattle and Renton, Washington. Dr. Fisher is the first sleep dentist in the Seattle area to offer Alesis OSA1, a breakthrough non-surgical treatment for patients with obstructive sleep apnea (OSA) who cannot tolerate CPAP therapy. Th
- OpenEvidence Integrates ASCO Guidelines, Figures and Flowcharts into Specialty Oncology Model27 May 2026, 4:00 pm
MIAMI--(BUSINESS WIRE)-- #ASCO--Today, OpenEvidence, the most widely used medical knowledge platform, announced an integration of ASCO Guidelines, figures, and flowcharts into the OpenEvidence model. As a part of OpenEvidence's commitment to creating advanced AI models for medical specialties, the company has extended their oncology model to include the ASCO Guidelines. ASCO Guidelines will now appear within OpenEvidence answers, accompanied by peer-reviewed evidence, precise citations, and a direct li
- Groundbreaking Headache Medicine Research on New Frontiers in Treatment, Biomarkers, and the Gut-Brain Axis to be Presented at the American Headache Society® 68th Annual Scientific Meeting27 May 2026, 2:41 pm
MOUNT ROYAL, N.J.--(BUSINESS WIRE)-- #AHSAM--Leading researchers and clinicians gather June 4–7 for the AHS 68th Annual Scientific Meeting, the premier scientific conference in headache medicine.
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach27 May 2026, 12:00 pm
ORLANDO, Fla.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, today announced the start of full operations of its newest CenterWell Pharmacy® mail order distribution center, in Orlando, Florida. The $83 million, state-of-the-art facility bolsters capacity for prescription medication delivery across Florida and the country and reinforces Humana’s longstanding commitment to providing members and patients across the Sunshine State with a simp
- Arima Genomics Announces Presentation of New Data at ASCO 2026 Supporting Clinical Utility of Hi-C Sequencing in Non-Small Cell Lung Cancer27 May 2026, 12:00 pm
CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago. The findings in the poster presentation demonstrate the value of Arima’s Hi-C sequencing-based approach to fusion and rearrangement detection, available clinically through t
- Viridian Therapeutics to Participate in Upcoming June Investor Conferences27 May 2026, 11:00 am
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare
- NationsBenefits Selected by Sam’s Club to Lead National Expansion of Modern Hearing Centers27 May 2026, 11:00 am
PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--NationsBenefits®, the leading healthcare fintech and outcomes platform, today announces its selection by Sam’s Club to manage all Sam’s Club hearing centers across the U.S. This collaboration integrates world-class technology and clinical expertise from NationsHearing® directly into the club to deliver advanced hearing care and outcomes-focused wellness care. These services are designed to improve overall well-being through a modern, member-centric experience
- GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference26 May 2026, 8:05 pm
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that management will participate in the Goldman Sachs Healthcare Conference from June 8-10 in Miami, FL.
- Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference26 May 2026, 8:05 pm
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Tuesday, June 9th, 2026, at 10:40am ET. A live webcast o
- Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference26 May 2026, 12:00 pm
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- NeoGenomics to Present New Research at ASCO Annual Meeting 202626 May 2026, 11:05 am
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will showcase nine scientific abstracts at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).
- Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting26 May 2026, 11:00 am
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company’s psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes’ proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 r
- OpenEvidence Launches Voice Mode: The First Native Speech-to-Speech Medical AI21 May 2026, 4:00 pm
MIAMI--(BUSINESS WIRE)-- #clinicalai--OpenEvidence, the most widely used medical AI platform among U.S. physicians, today launched Voice Mode, the first native speech-to-speech medical AI interface. With Voice Mode, OpenEvidence becomes the first multimodal medical AI offering a hands-free way for clinicians to ask questions aloud, and hear cited answers read back, on the same peer-reviewed evidence base. The feature is live in the OpenEvidence web and mobile apps and is free for all users. Physicians reach
- Massive Bio and BeeKeeperAI Deploy Federated Confidential Computing to Expand Oncology Trial Access Across Atlanta’s Underserved Communities21 May 2026, 2:15 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a leader in AI-enabled patient recruitment and oncology solutions, today announced expanded access to oncology clinical trials through AI-powered patient pre-screening leveraging a privacy-preserving clinical data collaboration infrastructure. The initiative enables Massive Bio's artificial intelligence-driven clinical trial matching capabilities to operate securely on sensitive cancer data within BeeKeeperAI’s privacy enhancing platform, EscrowAI
- Arrivo Bio to Present Clinical Data on Forvisirvat at 2026 ASCP Annual Meeting21 May 2026, 1:00 pm
MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio will be giving both an oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26–29 in Miami, Florida. The presentations will highlight Forvisirvat (SP-624), Arrivo’s first-in-class oral activator of the SIRT6 enzyme, currently in a Phase 2b/3 study for major depressive disorder, with data read out expected later this year. Prior Phase 2 data demonstrated a signal of efficacy
- QAD | Redzone Releases New CFO Guide to AI in Manufacturing, Challenging Industry to Focus on Financial Outcomes Over AI Hype21 May 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)--QAD | Redzone, the company delivering the leading manufacturing platform, powered by Agentic AI that executes work and decisions across the business, from the shop floor to the top floor, announced the release of A CFO’s Pragmatic Guide to AI in Mid-Market Manufacturing, a new executive white paper designed to help manufacturing leaders navigate the growing wave of AI investment with greater operational and financial discipline. The paper argues that while AI activity ac
- CAN Community Health Launches Healx Solutions to Expand Access in Specialty Therapy Services21 May 2026, 12:00 pm
TAMPA, Fla.--(BUSINESS WIRE)-- #340b--CAN Community Health, the nation’s leading resource in comprehensive health services, today announced a new business entity dedicated to helping health systems, hospitals, physician practices, and specialty clinics unlock the full potential of high-cost specialty therapies while improving patient access, operational efficiency, and long-term sustainability. Healx Solutions launches to support healthcare organizations navigating the growing complexity of specialty m
- Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem21 May 2026, 12:00 pm
BOSTON--(BUSINESS WIRE)--Ontada®, a business for oncology insights, announced the inclusion of Florida Cancer Specialists & Research Institute's data into its ecosystem.
- Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference21 May 2026, 11:15 am
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be av
- Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences21 May 2026, 11:00 am
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—and its ongoing involvement in sleep medicine. The data presented reflect Alkermes’ ongoing commitment to contributing to the advancement of patient care and expanding the body of evidence in neuroscience. The meetings included: The Psych
- CareDx to Participate in Upcoming Investor Conferences20 May 2026, 8:01 pm
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,
- ReCode Therapeutics Achieves a First: Proof of Activity in Primary Ciliary Dyskinesia Patients20 May 2026, 8:00 pm
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using lipid nanoparticle delivery to power the next wave of mRNA and gene correction therapeutics, today announced the presentation of clinical data from its RCT1100 PCD inhaled mRNA program at the American Thoracic Society (ATS) 2026 International Conference, held May 15-20, 2026, at the Orange County Convention Center in Orlando, FL. The data represent the first clinical evidence of biological
- CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors20 May 2026, 12:30 pm
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total
- Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 202620 May 2026, 12:15 pm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the poster presented. Poster Board 401: “Rel
- Autobahn Therapeutics Presents New Preclinical Data at ASCP Annual Meeting Demonstrating Elunetirom Drives Robust Bioenergetic and Neuroplastic Improvements in Neuronal Cultures20 May 2026, 12:00 pm
SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced the presentation of new preclinical data for elunetirom (ABX-002), the company’s lead asset currently in Phase 2 clinical development for adjunctive major depressive disorder (MDD) and bipolar depression, at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place in Miami Beach, F
- Starfighters Space, Inc. Files First Quarter 2026 Form 10-Q20 May 2026, 10:00 am
CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the innovative aerospace company, owner and operator of the world's largest fleet of commercial supersonic aircraft, is pleased to report its financial results for the first quarter of fiscal 2026 for the period ended March 31, 2026. To review the full financial results, please view the Company’s recent 10-Q filing with the U.S. Securities and Exchange Commission at www.sec.g
- Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)19 May 2026, 6:15 pm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reports long-term efficacy and safety data from the first 48 weeks of the ongoing OL treatment period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. IMPALA-2 is the longe
- Sensome Announces Positive First-in-Human Study Results for In Situ Tumor Detection Technology for Lung Cancer19 May 2026, 1:15 pm
PARIS--(BUSINESS WIRE)-- #cancer--Sensome announces positive first-in-human results for its in situ tumor detection technology for lung cancer.
- LivaNova to Present at Goldman Sachs Global Healthcare Conference in June19 May 2026, 12:00 pm
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on Mon., June 8, 2026, at 8 a.m. Eastern Daylight Time. The discussion will be
- CCS Unveils New Research at ISPOR 2026: Longitudinal Coaching and Education Sustain CGM Outcomes Beyond Initiation19 May 2026, 11:00 am
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--As healthcare providers and health plans grapple with growing continuous glucose monitoring (CGM) adoption and persistent gaps in diabetes outcomes alongside growing chronic care costs, a new research-driven poster from CCS is challenging the assumption that simply being prescribed a CGM device is enough. While CGM initiation is often associated with early improvements in glycemic control, new research from CCS suggests those improvements are not consisten
- Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)18 May 2026, 6:55 pm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise capacity data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the data presented
- Visium Powers the Next Generation of Healthy Buildings in America’s Model City18 May 2026, 4:59 pm
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--As West Palm Beach rapidly emerges as the next model American city, Visium, a leader in Far-UVC environmental control technology, is playing a central role in shaping how modern buildings support health, wellness, and productivity. Headquartered in the heart of CityPlace, Visium is deeply embedded within the transformation led by Related Ross, one of the country’s most influential real estate developers. With over $10 billion committed to Palm Beach Count
- Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 202618 May 2026, 3:30 pm
MORRISVILLE, N.C.--(BUSINESS WIRE)--Vast Therapeutics, a clinical-stage life science company developing nitric oxide-based medicines for serious lung diseases, today announced late-breaking Phase 1 data for its inhaled drug candidate ALX1, presented at the American Thoracic Society (ATS) 2026 International Conference in Orlando, Florida. The data demonstrates that ALX1, a first-in-class nitric oxide prodrug designed for targeted delivery to the lungs, was well tolerated without safety concerns
- Entanglement Chief Research Scientist Dr. Fred Glover Ranked #30 Worldwide in Research.com’s 2026 Best Mathematics Scientists List18 May 2026, 3:00 pm
MIAMI--(BUSINESS WIRE)-- #ai--Entanglement, Inc., a next-generation computing and AI company advancing quantum logic, optimization, and artificial intelligence, today announced that its Chief Research Scientist, Dr. Fred Glover, has been ranked #30 worldwide and #22 in the United States in Research.com’s 2026 Best Mathematics Scientists ranking. The fifth annual edition of the ranking evaluates more than 3,500 leading researchers across the mathematical sciences using the discipline-specific D-index,
- Fujifilm Launches the EB-710US, a Novel Next-Generation, Balloon-less Endobronchial Ultrasound (EBUS) Bronchoscope for Pulmonary Care18 May 2026, 12:00 pm
LEXINGTON, Mass.--(BUSINESS WIRE)--FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, today announced the launch of the EB-710US Ultrasound Bronchoscope, a novel next-generation endobronchial ultrasound (EBUS) solution designed to streamline workflow and enhance imaging performance for pulmonologists and healthcare systems. The new scope will be demonstrated at booth #1815 at the American Thoracic Society Conference (ATS), May 18-20 in
- Ideagen becomes Games first AI Technology Principal Partner and backs Commonwealth Netball18 May 2026, 12:00 pm
NOTTINGHAM, England--(BUSINESS WIRE)-- #AI--Ideagen, a global software company with its US headquarters in Fort Lauderdale, has been unveiled as the Official AI Technology Principal Partner of Glasgow 2026, Presenting Partner for Netball and an Official Partner for Team Scotland, becoming one of the primary sponsors of the UK’s biggest sporting event this year. Launched in 2009, Ideagen technology sits at the heart of quality, safety and compliance in the world's most regulated and high-compliance in
- Secretome Therapeutics Announces Participation in Upcoming Summer Investor Conferences15 May 2026, 2:46 pm
PLANO, Texas--(BUSINESS WIRE)-- #Biotech--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that members of its management team will participate in three upcoming investor conferences this summer. Secretome is scheduled to attend the following conferences: Jefferies Global Healthcare Conference June 2 – 4, 2026 New York, New York Oppenheimer CNS & Neuro-Muscular Summi
- NeoGenomics to Participate in Upcoming Investor Conferences15 May 2026, 1:05 pm
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis Investor 1x1 meetings on Thursday, May 28th The Jefferies Global Healthcare Conference 2026 in New York Fireside chat on Thursday, June 4th, at 10:30am EDT, and investor 1x1 meetings A w
- Massive Bio and Just Worldwide Announce Strategic Partnership to Connect More Cancer Patients to Clinical Trials14 May 2026, 2:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, the global leader in AI-driven clinical trial matching for cancer patients, and Just Worldwide, a leading global fieldwork and market research provider specializing in healthcare, biotech, life sciences, and pharmaceutical sectors, today announced a strategic partnership focused on connecting cancer patients to clinical trial opportunities through patient communities, advocacy groups, and patient organizations. Under the agreement, Just Worldwide
- Cord for Life® Completes the First Clinical Trial Using Cord Blood Stem Cells for a Non-Transplant Medical Treatment of Lower Back Pain14 May 2026, 12:41 am
ALTAMONTE SPRINGS, Fla.--(BUSINESS WIRE)-- #BiotechInnovation--In a historical moment for umbilical cord blood stem cell research, Cord for Life®, Inc. announces the completion of phase 1 of a clinical trial for lower back pain treatment. This marks the first time umbilical cord blood stem cells have been evaluated for a treatment not related to transplantation and regeneration of the recipient’s bone marrow to generate new blood cells. This early success could lead to numerous other trials for a wide range of trea
- OrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development and Manufacturing Organization13 May 2026, 4:03 pm
MIAMI--(BUSINESS WIRE)--OrganaBio, LLC ("OrganaBio"), a manufacturer of GMP cells and blood products and provider of cell isolation and cryopreservation services, has acquired substantially all of the operating assets of San Diego-based Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization. Newly formed OrganaBio subsidiary Excellos Labs, LLC (“Excellos Labs”) will be responsible for San Diego operations going forward. The acquisition creates a mor
- LaVoie Announces USPTO Renewal of Trademark Registrations for Two Proprietary Communications Methodologies13 May 2026, 2:12 pm
BOSTON & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #DigitalCommunications--LaVoie announces trademark renewal for its LHS Immersion® and The LHS Fifteen-Slide Presentation® communications methodologies
- Catalyst OrthoScience Appoints Gordon Van Ummersen to Board of Directors13 May 2026, 2:00 pm
NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the appointment of Gordon Van Ummersen to its board of directors. “I am pleased to join Catalyst OrthoScience’s board at this important stage of the company’s evolution,” said Van Ummersen. “Catalyst is an exciting shoulder-focused company that has built a compelling platform focused o
- Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing13 May 2026, 12:00 pm
TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic partnership to support late-phase manufacturing of Elpida’s lead program, an AAV9 gene therapy for Spastic Paraplegia Type 50 (SPG50). Under the agreement, Catalent will also be granted exclusive manu
- TherapeuticsMD Announces First Quarter 2026 Financial Results12 May 2026, 8:05 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025. License Revenues from Continuing Operations T
- OutcomeRx Launches Innovative Targeted Stop-Loss Insurance Product Covering CAR T-Cell and Gene Therapies12 May 2026, 5:13 pm
ORLANDO, Fla.--(BUSINESS WIRE)--OutcomeRx Insurance Management Services, LLC today announced the launch of CGT Solutions Stop-Loss, a stand-alone medical stop-loss insurance product that reimburses covered expenses on qualified claims for Gene and CAR T-cell therapies for group health plans and their coordinating Stop-Loss carrier. This innovative solution, in addition to reimbursement for certain FDA approved Prescription Drugs, uniquely reimburses administration of the Prescription Drug and t
- PriceMDs Launches Industry-First API Integration Platform to Simplify Specialty Medication Sourcing and Tracking12 May 2026, 2:07 pm
CLEARWATER, Fla.--(BUSINESS WIRE)--PriceMDs today announced the launch of a new API integration platform designed to help pharmacy benefit managers (PBMs), third-party administrators (TPAs), and healthcare organizations streamline prescription sourcing and specialty medication management within their existing workflows. The platform connects pricing, patient onboarding, regulatory documentation, shipment tracking, and claims reporting into a single integration, reducing the need for manual proc
- HSS Research Supports Routine Imaging Before and After ACL Surgery in Growing Children12 May 2026, 1:36 pm
ORLANDO, Fla.--(BUSINESS WIRE)--At this year’s Pediatric Orthopedic Society of North America (POSNA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies evaluating outcomes for three of the most common anterior cruciate ligament (ACL) reconstruction techniques designed to protect open growth plates in young patients who are still growing. The findings highlight the importance of using imaging before and after surgery to accurately identify and monitor alignme
- Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference11 May 2026, 8:05 pm
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 20
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 202611 May 2026, 8:01 pm
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2026. “Since the inception of our immunology portfolio targeting type 2 diseases, our team has worked diligently to advance highly selective inhibitors of KIT, STAT6 and MRGPRX2 designed to enable convenient or
- Alesis LLC Announces First Sleep Center Partnership for Alesis OSA1™ Treatment of the Root Cause of Most Sleep Apnea11 May 2026, 5:08 pm
COCOA BEACH, Fla. & MOORESVILLE, N.C.--(BUSINESS WIRE)--Alesis LLC, the U.S. distributor of the Alesis OSA1™ medical device and headquartered on Florida’s Space Coast in Cocoa Beach, today announced a joint venture partnership with Lake Norman Pulmonary & Sleep in Mooresville, North Carolina — making it the first sleep medicine practice in the Piedmont region to offer Alesis OSA1, a breakthrough non-surgical treatment for patients with obstructive sleep apnea (OSA) who cannot tolerate CPAP
- OpenEvidence and Society of Surgical Oncology Announce Strategic Partnership to Advance Surgical Cancer Care and Launch SSO Innovator Grant11 May 2026, 4:00 pm
MIAMI & ROSEMONT, Ill.--(BUSINESS WIRE)-- #MedicalAI--Today, the Society of Surgical Oncology (SSO), a global professional society for cancer surgeons, and OpenEvidence, the most widely used medical knowledge platform, announced a strategic partnership to strengthen access to the most trusted surgical oncology evidence at the point of care while building a foundation for innovative collaborations to support surgeons and all physicians taking care of patients with cancer. Together, SSO and OpenEvidence will
- LTM Introduces SAP Centric AI Powered Platform to Orchestrate Intelligent, Autonomous Enterprise Operations11 May 2026, 1:45 pm
MUMBAI, India & ORLANDO, Fla.--(BUSINESS WIRE)---- $LTM #AI--LTM today announced the launch of the LTM Business Orchestration platform to orchestrate intelligent and autonomous enterprise operations across SAP.
- United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 202611 May 2026, 10:30 am
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando. “We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieve
- Coolibar and Skin Cancer Survivor and Advocate, Dayanara Torres, Redefine Life in the Sun for Skin Cancer Awareness Month8 May 2026, 8:31 pm
MIAMI--(BUSINESS WIRE)-- #Coolibar--Coolibar, the world’s leading UPF 50+ sun protection apparel brand, is continuing its partnership with skin cancer survivor and advocate Dayanara Torres and the Melanoma Research Foundation (MRF) for Skin Cancer Awareness Month this May. The 2026 campaign brings a more intimate and elevated creative direction to Coolibar’s sun safety message, using emotional storytelling to encourage prevention, protection, and early detection. Together, the partners aim to reach communi
- Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American8 May 2026, 8:00 pm
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Co
- Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology8 May 2026, 3:18 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced that SkinCure Oncology and Sensus Healthcare have amicably resolved their dispute and are moving forward constructively with a shared commitment to patient care and clinical excellence. In March 2026, Sensus Healthcare filed a lawsuit in the Circuit Court for the Fifteenth Judicial Cir
- Bruno Vision Care Wins 2026 MedTech Breakthrough Award8 May 2026, 2:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #ContactLenses--Bruno Vision Care's FDA-cleared Deseyne® Extended Depth of Focus daily disposable contact lens for presbyopia wins 2026 MedTech Breakthrough Award.
- Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights7 May 2026, 8:05 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026. Highlights included: Revenue of $3.4 million compared to $8.3 million for the three months ended March 31, 2025. Excluding sales to the Company’s historically largest customer, rev
- Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights7 May 2026, 8:05 pm
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for
- Catalyst Fracture System Wins Medical Device Engineering Breakthrough Designation in 2026 MedTech Breakthrough Awards Program7 May 2026, 2:00 pm
NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that the Catalyst Fracture System received the “Medical Device Engineering Breakthrough” award in the 10th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies
- Alnylam to Webcast Presentations at Upcoming Investor Conferences7 May 2026, 12:00 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida. A live audio webcast of each presentation will be
- Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences6 May 2026, 1:00 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
- Gilead's Earnings Skyrocket as Florida’s AIDS Drug Program Falters, says AHF5 May 2026, 6:40 pm
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--Gilead's Earnings per Share Expected to Be Up 52% as Florida’s and other States’ AIDS Drug Programs Falters, says AHF
- The Global Initiative for Asthma and OpenEvidence Partner to Deliver Asthma Strategy to Physicians Worldwide5 May 2026, 4:00 pm
FONTANA, Wis. & MIAMI--(BUSINESS WIRE)-- #Asthma--The Global Initiative for Asthma (GINA) collaborates with OpenEvidence to make GINA’s evidence-based asthma strategy reports, clinical recommendations, and educational resources available directly through OpenEvidence. Under the agreement, OpenEvidence becomes a key content partner for GINA, driving the digital dissemination of asthma standards to clinicians across OpenEvidence’s rapidly expanding international footprint. Asthma affects more than 300 mill
- Call 4 Health Awarded Call Center Services Agreement With Premier, Inc.5 May 2026, 3:58 pm
DELRAY BEACH, Fla.--(BUSINESS WIRE)--Call 4 Health has been awarded a national group purchasing agreement for Call Center Services with Premier, Inc. Effective February 1, 2026, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Medical Answering, Appointment Scheduling, Telephone Nurse Triage, and Clinical Trial Recruitment and Retention services. “Being selected by Premier is a meaningful milestone for Ca
- Precision IO Group Launches U.S. Clinical Study of Epione® Robotic System for the Treatment of Bone Lesions5 May 2026, 1:34 pm
MIAMI--(BUSINESS WIRE)--Precision IO Group, the parent company of Quantum Surgical, announced the launch of EPIOS, a new U.S. clinical study evaluating the safety and performance of the Epione® robotic platform for the treatment of bone tumors and metastases. The study is designed to support the expansion of Epione’s market approvals in the United States. The first patient was treated on April 28, 2026, in a leading cancer center based in Miami, Florida. Epione has been CE marked for bone indic
- South Florida Community Rallies to Raise a Record $1.7 Million at FedEx/St. Jude Angels and Stars Gala5 May 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)--The FedEx/St. Jude Angels and Stars Gala united the Miami and South Florida community, raising a record $1.7 million for St. Jude Research Hospital.
- Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress5 May 2026, 11:01 am
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2026. “Our team continues its strong execution across our portfolio as we are launch ready ahead of veligrotug’s PDUFA target date. We delivered positive topline data fro
- OpenEvidence and ACOG Announce Strategic Collaboration to Advance Ob-Gyn Health Care4 May 2026, 4:00 pm
MIAMI & WASHINGTON--(BUSINESS WIRE)--Today, OpenEvidence and American College of Obstetricians & Gynecologists (ACOG) announced a strategic collaboration to expand access to ACOG’s evidence-based clinical guidance and develop insights to help inform the future of ob-gyn care and women’s health. The collaboration brings together ACOG, the leading professional membership organization and author of clinical guidance for obstetrician–gynecologists, and OpenEvidence, the most widely used medical
- Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 20264 May 2026, 11:00 am
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS) International Conference 2026 being held May 15-20, 2026 in Orlando, Fl
- Trividia Health Correction for TRUE METRIX Blood Glucose Monitoring Systems1 May 2026, 6:00 pm
FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--Trividia Health, Inc., a global leader in diabetes management, today provided an important update to the medical device labeling correction it announced on February 6, 2026, for all TRUE METRIX®, TRUE METRIX® AIR, TRUE METRIX® GO, and TRUE METRIX® PRO Blood Glucose Monitoring Systems (collectively, the “Products”). Since the February 6, 2026 communication, Trividia Health has been actively updating the labeling and providing messaging to ensure that users
- Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program1 May 2026, 12:00 pm
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, along with its affiliated health plans, today announced 45 distinguished medical practices and health systems to be honored in its annual Care Provider Recognition Program. The program spotlights the top one percent of primary care providers in Elevance Health’s nationwide affiliated health plan network of about 7,200 value-based care and evaluated provider partners. The recognition highlights primary care providers who exhibit excellence in deliv
































































































































































































































